Feature | February 27, 2013

Oncology Information Systems' Reporting and Alerts Leave Providers Wanting More

As meaningful use and ACOs pick up steam, oncology providers contend with regulatory pressures with or without help from their vendors

Oncology Information Management Systems KLAS Meaningful Use Reports Alert

February 27, 2013 — Alerts and reporting are two of the most challenging aspects of medical oncology, in addition to being the tools providers are least happy with overall. This is according to a new report from KLAS titled Oncology 2012: Pulling the Curtain Back.

Study findings reveal that oncology information system vendors struggle with alerts. Specifically, Epic, Varian and Elekta seem to perform below average. Reporting is also an area for improvement. Providers report that Varian and Elekta's canned reports are not robust enough to meet their needs, and the customized reports are difficult to use. Epic's customized reports are not as user friendly as providers would like them to be.

Meaningful use (MU) is another hot button for providers. The vast majority of oncology providers interviewed indicate that they are planning to attest for MU, but according to the report, vendors differ in their ability to partner with providers in that effort. Altos and BMSi are the best reported MU partners because they are more hands on and appear to be more focused on customer needs.

Though Varian is one of the dominant players in the oncology IT market, the report indicates that they are not the best MU partner. The MU version of Varian ARIA did not come out on the promised timeline, and some providers report that Varian seems out of touch with customers. Additionally, Epic is identified as a vendor that could improve due to the fact that the system is not designed for all the needs of oncology providers.

With MU Stage 2 bearing down, patient portals are also identified as an important consideration for oncology providers. Only 30 percent of those surveyed said they are currently using a patient portal, and many still need to make that decision.

"Most of the Epic and Altos customers in the study said they are using patient portals; however, we spoke with only a small number of those customers," said Monique Rasband, oncology research director and author of the report. "The majority of Elekta and Varian customers have not yet adopted a portal. Most Varian and Elekta customers said they are looking to their current oncology IT vendor to supply a portal, in spite of most portals being rudimentary at this point."

This study includes ratings on medical and radiation oncology IS vendors. Vendors rated in radiation oncology are BMSi, Elekta and Varian. Vendors rated in medical oncology are Altos (early data), Elekta, Epic, IntrinsiQ and Varian. To learn more about the oncology IS market and the vendors in this study, providers and vendors can review the full report Oncology IT: Pulling the Curtain Back. This report is available to healthcare providers at a significant discount.

For more information: www.KLASresearch.com/KLASreports

Related Content

ACR Select, Appropriateness Criteria, federal AUC requirements, qPLEs
News | Clinical Decision Support | June 23, 2016
The Centers for Medicare & Medicaid Services (CMS) has named the American College of Radiology (ACR) a “qualified...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of...
intelerad, IntelePACS, enterprise imaging, Radiology Imaging Associates
Sponsored Content | Case Study | Enterprise Imaging | June 14, 2016
Founded by a small group of radiologists in 1968, Radiology Imaging Associates P.C. has played a role in shaping the...
Fraunhofer MEVIS, radiation therapy efficiency, SPARTA project
News | Radiation Therapy | June 09, 2016
The Fraunhofer Institute for Medical Image Computing MEVIS in Bremen, Germany, recently completed a project to develop...
News | Vendor Neutral Archive (VNA) | June 08, 2016
Mach7 Technologies announced it has been named a Leader in the IDC MarketScape: U.S. Healthcare Provider VNA/AICA...
Logicalis, telehealth, user experience, recommendations
News | Teleradiology | June 07, 2016
A new report from Logicalis Healthcare Solutions discusses six ways telehealth providers can enhance the patient...
Technology | Clinical Decision Support | June 07, 2016
Healthy Interactions and MedCurrent recently introduced a first-of-its-kind clinical decision support platform that...
Overlay Init